Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 11;2:48. doi: 10.1038/s43856-022-00114-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Comparison of antibody response to 15 epitopes in samples taken before (n = 6, MelVac-CTRL) and after vaccination (n = 6, MelVac) in six MelCancerVac® receiving patients (MelVac1-MelVac6). x-axis denotes 15 epitopes as biomarkers (M1-M15), y-axis (Abundance ratio) shows the ratio of abundance values of IgG-bound peptides between paired MelVac and MelVac-CTRL samples of the patient (MelVac_i[M_abundance + 1]/MelVac-CTRL_i[M_abundance + 1], i – number of patient, M – biomarker) in base 10 logarithmic scale. Dashed line indicates ratio value 0 (1 in linear scale), i.e., where antibody reactivity to peptides containing the specific epitopes remained unchanged in MelCancerVac® post-vaccination cohort. Values > 0 indicate rise in seroreactivity after vaccination while <0 indicates decrease. Source abundance values for each epitope are presented in Supplementary Data 5. b Vaccine-dependent antibody response enhancement to the resolved epitopes was common. Data are shown for epitopes M4 and M5 by comparing abundances of IgG-bound peptides from the vaccinated patients, before (MelVac-CTRL) and after vaccination (MelVac). Abundance – number of IgG-bound peptides containing the specified epitope sequence detected in the sample. Two-tailed paired Wilcoxon Rank Sum test, * p < 0.05, p-values not adjusted for multiple comparisons. c Box plots show the abundance of IgG-bound peptides containing the specified epitopes (M1, M3, M9, M13, and M14) upon MVA competition analysis. MelVacComp – data from competition with DDM-1.7 melanoma cell lysate is shown. Relative abundance – the abundance of IgG-bound peptides containing the specified epitopes normalized to values of the paired vaccination-specific sample (MelVac) for each patient. d Box plots show the abundance of IgG-bound peptides containing sequences of the viral capsid antigen p18 (EBV VCA p18 epitope (₁₆₁ GGQPHDTAPRGARKK ₁₇₅) and the epitope of glycoprotein B (CMV gB; ₇₀ ETIYNTTLKY ₈₀)⁴⁰ from MVA competition analysis. MelVacComp – data from competition with DDM-1.7 melanoma cell lysate is shown. Abundance – the abundance of IgG-bound peptides containing the specified epitopes in base 10 logarithmic scale.